Xenical (orlistat) Disease Interactions
There are 4 disease interactions with Xenical (orlistat):
Orlistat (Includes Xenical) ⇔ Malabsorption
Severe Potential Hazard, High plausibility
Applies to: Malabsorption Syndrome, Biliary Obstruction
The use of orlistat is contraindicated in patients with chronic malabsorption syndrome or cholestasis. Orlistat can worsen the malabsorption in these conditions by reversibly inhibiting lipases that are necessary for the hydrolysis of triglycerides into absorbable free fatty acids and monoglycerides. At the recommended therapeutic dosage of 120 mg three times a day, orlistat inhibits dietary fat absorption by approximately 30%.
Orlistat (Includes Xenical) ⇔ (Fat Soluble) Vitamin Deficiency
Moderate Potential Hazard, High plausibility
Applies to: Vitamin A Deficiency, Vitamin D Deficiency, Vitamin K Deficiency
At the recommended therapeutic dosage of 120 mg three times a day, orlistat inhibits dietary fat absorption by approximately 30% and has been shown to reduce the absorption of some fat-soluble vitamins and beta-carotene. Therapy with orlistat should be administered cautiously in patients with preexisting deficiency of one or more fat-soluble vitamins (A, D, E and K). Ideally, the deficiency should be corrected prior to initiation of therapy. A multivitamin supplement containing fat-soluble vitamins is recommended during therapy, best taken once a day at least 2 hours before or after the administration of orlistat.
Orlistat (Includes Xenical) ⇔ Nephrolithiasis
Moderate Potential Hazard, Moderate plausibility
Applies to: Nephrolithiasis
Following treatment with orlistat, some patients may develop increased levels of urinary oxalate as a result of fat malabsorption. Therapy with orlistat should be administered cautiously in patients with a history of hyperoxaluria or calcium oxalate nephrolithiasis.
Obesity Drugs (Includes Xenical) ⇔ Diabetics
Minor Potential Hazard, Moderate plausibility
Applies to: Diabetes Mellitus
Obese, diabetic patients who achieve weight loss may demonstrate improved metabolic control of their disease as a result of their reduced weight. Therefore, overweight patients with diabetes mellitus should be monitored during weight-reduction therapy (or therapy that may be expected to induce weight loss as a secondary effect) for reduced need of oral hypoglycemic medication or insulin, and the dosages of these agents adjusted accordingly.
You should also know about...
Xenical (orlistat) drug Interactions
There are 28 drug interactions with Xenical (orlistat)
Xenical (orlistat) food/lifestyle Interactions
There is 1 food/lifestyle interaction with Xenical (orlistat)
See also...
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2009 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
